In addition, metformin has been demonstrated to overcome primary resistance to the anti-HER2 monoclonal antibody trastuzumab, both in 3D mammosphere cultures and in HER2-positive breast cancer xenografts [85,86]. This evidence concerns the gene ERBB2 and breast carcinoma.